This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asatiani, E. Articles by Gelmann, E. P. Search for Related Content PubMed PubMed Citation Articles by Asatiani, E. Articles by Gelmann, E. P.

Deletion, Methylation, and Expression of the NKX3.1 Suppressor Gene in Primary Human Prostate Cancer

Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia

Requests for reprints: Edward P. Gelmann, Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, NW, Washington, DC 20007-2197. Phone: 202-444-2207; Fax: 202-444-1229; E-mail: Gelmanne{at}georgetown.edu.

NKX3.1 is a prostate-specific homeoprotein and tumor suppressor that is affected by the loss of 8p21 in prostate cancer. In mice, Nkx3.1 haploinsufficiency results in prostatic dysplasia and complements cancer formation induced by loss of other suppressor genes. However, NKX3.1 expression can be immunohistochemically detected in most primary prostate cancers. We examined the relationship between suppressor gene haploinsufficiency, methylation, and quantitative NKX3.1 expression levels in primary prostate cancer. NKX3.1 gene copy number was assessed by microsatellite analysis, fluorescence in situ hybridization, and quantitative PCR. NKX3.1 gene methylation was determined in prostate cancer cell lines and we thereby identified potential CpG methylation sites for methylation-specific PCR analysis in tissues. We validated and then applied an internally controlled fluorescence immunomicroscopic assay for NKX3.1 protein expression in 48 primary prostate cancer specimens from radical prostatectomies. NKX3.1 loss of heterozygosity was found in 27 of 43 tissues tested. Classic CpG island methylation of the NKX3.1 gene was not found in either prostate cancer cell lines or tissues. However, in 33 of 40 samples tested, CpG sites at –921, –903, and –47 were methylated to a greater degree in malignant than in adjacent normal cells. In 43 of 48 samples, NKX3.1 protein expression was reduced from 0.34 to 0.90 compared with adjacent normal luminal epithelium (mean of all samples, 0.68; 95% confidence interval, 0.05). In 12 cases that also had high-grade prostatic intraepithelial neoplasia, NKX3.1 expression levels were similar in preinvasive and invasive cancer cells and significantly lower than adjacent normal cells. Even in the presence of allelic loss, NKX3.1 expression is reduced over a wide range in prostate cancer at the time of prostatectomy, suggesting that diverse factors influence expression. Samples with protein expression below the median level in cancer cells had both NKX3.1 deletion and selective CpG methylation.

Key Words: NKX3.1 • prostate cancer • haploinsufficiency • confocal microscopy • methylation

This article has been cited by other articles:

				E. P. Rahrmann, L. S. Collier, T. P. Knutson, M. E. Doyal, S. L. Kuslak, L. E. Green, R. L. Malinowski, L. Roethe, K. Akagi, M. Waknitz, et al. Identification of PDE4D as a Proliferation Promoting Factor in Prostate Cancer Using a Sleeping Beauty Transposon-Based Somatic Mutagenesis Screen Cancer Res., May 15, 2009; 69(10): 4388 - 4397. [Abstract] [Full Text] [PDF]

				E. Muhlbradt, E. Asatiani, E. Ortner, A. Wang, and E. P. Gelmann NKX3.1 Activates Expression of Insulin-like Growth Factor Binding Protein-3 to Mediate Insulin-like Growth Factor-I Signaling and Cell Proliferation Cancer Res., March 15, 2009; 69(6): 2615 - 2622. [Abstract] [Full Text] [PDF]

				H. Zhang, M. H. Muders, J. Li, F. Rinaldo, D. J. Tindall, and K. Datta Loss of NKX3.1 Favors Vascular Endothelial Growth Factor-C Expression in Prostate Cancer Cancer Res., November 1, 2008; 68(21): 8770 - 8778. [Abstract] [Full Text] [PDF]

				M. C. Markowski, C. Bowen, and E. P. Gelmann Inflammatory Cytokines Induce Phosphorylation and Ubiquitination of Prostate Suppressor Protein NKX3.1 Cancer Res., September 1, 2008; 68(17): 6896 - 6901. [Abstract] [Full Text] [PDF]

				Y. Zhang, R. A. Fillmore, and W. E. Zimmer Structural and Functional Analysis of Domains Mediating Interaction Between the Bagpipe Homologue, Nkx3.1 and Serum Response Factor Experimental Biology and Medicine, March 1, 2008; 233(3): 297 - 309. [Abstract] [Full Text] [PDF]

				B. Guan, P. Pungaliya, X. Li, C. Uquillas, L. N. Mutton, E. H. Rubin, and C. J. Bieberich Ubiquitination by TOPORS Regulates the Prostate Tumor Suppressor NKX3.1 J. Biol. Chem., February 22, 2008; 283(8): 4834 - 4840. [Abstract] [Full Text] [PDF]

				Y. Peng, C. X. Li, F. Chen, Z. Wang, M. Ligr, J. Melamed, J. Wei, W. Gerald, M. Pagano, M. J. Garabedian, et al. Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70 Am. J. Pathol., January 1, 2008; 172(1): 225 - 235. [Abstract] [Full Text] [PDF]

				C. Bowen, A. Stuart, J.-H. Ju, J. Tuan, J. Blonder, T. P. Conrads, T. D. Veenstra, and E. P. Gelmann NKX3.1 Homeodomain Protein Binds to Topoisomerase I and Enhances Its Activity Cancer Res., January 15, 2007; 67(2): 455 - 464. [Abstract] [Full Text] [PDF]

				C. R. Bethel, D. Faith, X. Li, B. Guan, J. L. Hicks, F. Lan, R. B. Jenkins, C. J. Bieberich, and A. M. De Marzo Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion. Cancer Res., November 15, 2006; 66(22): 10683 - 10690. [Abstract] [Full Text] [PDF]

				H. Gao, X. Ouyang, W. A. Banach-Petrosky, W. L. Gerald, M. M. Shen, and C. Abate-Shen Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer PNAS, September 26, 2006; 103(39): 14477 - 14482. [Abstract] [Full Text] [PDF]

				M. Singh and L. Johnson Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res., September 15, 2006; 12(18): 5312 - 5328. [Abstract] [Full Text] [PDF]

				T. Rauch, H. Li, X. Wu, and G. P. Pfeifer MIRA-Assisted Microarray Analysis, a New Technology for the Determination of DNA Methylation Patterns, Identifies Frequent Methylation of Homeodomain-Containing Genes in Lung Cancer Cells Cancer Res., August 15, 2006; 66(16): 7939 - 7947. [Abstract] [Full Text] [PDF]

				S. L. Zheng, J.-h. Ju, B.-l. Chang, E. Ortner, J. Sun, S. D. Isaacs, J. Sun, K. E. Wiley, W. Liu, M. Zemedkun, et al. Germ-Line Mutation of NKX3.1 Cosegregates with Hereditary Prostate Cancer and Alters the Homeodomain Structure and Function Cancer Res., January 1, 2006; 66(1): 69 - 77. [Abstract] [Full Text] [PDF]